Pancreatic cancer remains a fatal disease in the majority of patients. The era of personalized medicine is upon us: customizing therapy according to each patient's individual cancer. Potentially, therapy can be targeted at individuals who would most likely have a favorable response, making it more efficacious and cost effective. This is particularly relevant for pancreatic cancer, which currently portends a very poor prognosis. However, there is much to be done in this field, and more studies are needed to bring this concept to reality.Keywords Chemotherapy, genomic profile, genomics, molecular pancreatic pathogenesis, pancreatic cancer pharmacogenomics, pancreatic exocrine cancer, targeted therapyAnn Gastroenterol 2017; 30 (1): 54-61
(EN)
